Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyAetna omalizumab (Xolair) Coverage Update | OpenPa…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0670

    Omalizumab (Xolair) coverage

    Customize your policy alerts

    Sign up for Aetna Policy 0670 alerts

    Get alerted when Policy 0670 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, precertification, prescribing specialist requirements, indications, continuation criteria, and coding guidance for omalizumab (Xolair) for commercial medical plans.

    Policy Summary
    PayerAetna
    PolicyOmalizumab (Xolair) coverage
    Policy CodePolicy 0670
    Change TypeNo material changes
    Effective DateSep 5, 2003
    Last ReviewAug 2, 2023
    Next Review DateMay 23, 2024
    Key ActionObtain precertification and document indication, age, relevant testing (IgE or allergen sensitization when indicated), prior therapies, and maintenance plan.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    J2357HCPCS code
    6+Asthma age
    12+CSU age
    18+CRSwNP age
    30–700 IU/mLIgE range
    0.1–0.2%Anaphylaxis risk

    Coverage Criteria

    Asthma - Initial Approval

    Covered when ALL of the following are met

    Asthma initial criteria: Member is 6 years of age or older; and member has a positive skin test or in vitro reactivity to at least one perennial aeroallergen; and member has a pre-treatment IgE level greater than or equal to 30 IU/mL; and member has uncontrolled asthma demonstrated by at least one of the following within the past year: two or more exacerbations requiring oral or injectable corticosteroid treatment, or one or more exacerbations resulting in hospitalization or emergency medical care visit, or poor symptom control (frequent symptoms or reliever use, activity limited by asthma, night waking due to asthma); and member has inadequate asthma control despite current treatment with both a medium-to-high-dose inhaled corticosteroid and an additional controller at optimized doses (eg, LABA, LAMA, leukotriene modifier, or sustained-release theophylline); and member will continue maintenance asthma treatments in combination with Xolair;

    Chronic Spontaneous Urticaria - Initial Approval

    Covered when ALL of the following are met

    CSU initial criteria: Member is 12 years of age or older; and member remains symptomatic despite up-dosing of a second-generation H1 antihistamine (in accordance with guideline recommendations, including consideration of up-dosing up to 4x) for at least 2 weeks; and member has been evaluated for other causes of urticaria (including bradykinin-related angioedema and IL-1-associated urticarial syndromes such as urticarial vasculitis); and member has experienced spontaneous onset of wheals (hives), angioedema, or both for at least 6 weeks;
    Policy Summary
    PayerAetna
    PolicyOmalizumab (Xolair) coverage
    Policy CodePolicy 0670
    Change TypeNo material changes
    Effective DateSep 5, 2003
    Last ReviewAug 2, 2023
    Next Review DateMay 23, 2024
    Key ActionObtain precertification and document indication, age, relevant testing (IgE or allergen sensitization when indicated), prior therapies, and maintenance plan.
    SourceLink
    On This Page
    Coverage CriteriaCoding GuidanceProvider Actions & Prior AuthorizationBackgroundDefinitionsCoding & Billing SummaryRevision History

    Chronic Rhinosinusitis with Nasal Polyps - Initial Approval

    Covered when ALL of the following are met

    CRSwNP initial criteria: Member is 18 years of age or older; and member has bilateral nasal polyps and chronic sinusitis symptoms despite intranasal corticosteroid treatment for at least 2 months unless contraindicated or not tolerated; and member has one of: bilateral nasal endoscopy/ anterior rhinoscopy/CT showing polyps reaching below the lower border of the middle turbinate or beyond in each nostril, or Meltzer Clinical Score >=2 in both nostrils, or total endoscopic nasal polyp score (NPS) >=5 with minimum 2 in each nostril; and member has nasal blockage/congestion/obstruction plus at least one additional symptom (rhinorrhea, reduction or loss of smell, or facial pain/pressure); and member will continue daily intranasal corticosteroid while treated unless contraindicated;

    Immune Checkpoint Inhibitor-Related Toxicity - Initial Approval

    Covered when BOTH of the following are met

    ICI-related toxicity criteria: Member has a refractory case of immune checkpoint inhibitor-related severe (grade 3) pruritus; and member has elevated IgE levels;

    Systemic Mastocytosis - Initial Approval

    Covered when BOTH of the following are met

    Systemic mastocytosis criteria: Major and at least one minor diagnostic criterion for systemic mastocytosis are present OR three or more minor diagnostic criteria are present (per WHO criteria); and the requested medication will be used in any of the following settings: stepwise prophylactic treatment for chronic mast cell mediator–related cardiovascular and pulmonary symptoms after trials of both H1 and H2 blockers and corticosteroids, or prevention of recurrent unprovoked anaphylaxis, or prevention of hymenoptera or food-induced anaphylaxis with negative specific IgE or skin test, or to improve tolerability of venom immunotherapy;

    Continuation of Therapy - General

    Covered when ALL of the following are met

    Continuation general: All members requesting continuation must meet all initial authorization criteria; and member cannot use omalizumab concomitantly with any other biologic or targeted synthetic drug for the same indication;

    Continuation of Therapy - Asthma

    For asthma continuation

    Asthma continuation: Member is 6 years of age or older; and asthma control has improved on Xolair as demonstrated by reduction in frequency and/or severity of symptoms or exacerbations, or reduction in daily maintenance oral corticosteroid dose; and member will continue maintenance asthma treatments (eg, inhaled corticosteroid and additional controller) in combination with Xolair;

    Continuation of Therapy - CSU

    For CSU continuation

    CSU continuation: Member is 12 years of age or older; and member has experienced a response since initiation of therapy (eg, improved symptoms, decrease in UAS7);

    Continuation of Therapy - CRSwNP

    For CRSwNP continuation

    CRSwNP continuation: Member is 18 years of age or older; and member has experienced a response as evidenced by improvement in signs and symptoms (eg, nasal congestion, reduction in polyp size, improvement in smell, rhinorrhea, sinonasal inflammation, hyposmia, facial pressure/pain or reduction in corticosteroid use); and member will continue daily intranasal corticosteroid while being treated unless contraindicated;

    Initial therapy — Allergic asthma

    Covered when ALL of the following are met for allergic asthma:

    FDA asthma indication core criteria: Patient is ≥6 years of age AND has moderate to severe persistent asthma AND has positive skin test or in vitro reactivity to a perennial aeroallergen AND symptoms are inadequately controlled with inhaled corticosteroids;age ≥6; IgE measured 30–700 IU/mL; weight ≤150 kg

    Dose determined by baseline IgE and body weight; not indicated for acute bronchospasm or status asthmaticus.

    Initial therapy — Chronic spontaneous urticaria

    Covered when ALL of the following are met for chronic spontaneous urticaria (CSU):

    CSU criteria: Patient is ≥12 years of age AND has chronic spontaneous or idiopathic urticaria for >6 weeks AND remains symptomatic despite treatment with H1-antihistamines at licensed doses (including consideration of up-dosing up to 4x);age ≥12; trial of H1 antihistamines (updosing allowed)

    Randomized controlled trial evidence supports omalizumab 300 mg every 4 weeks for treatment-refractory CSU up to 6 months.

    Initial therapy — Chronic rhinosinusitis with nasal polyps

    Covered when ALL of the following are met for chronic rhinosinusitis with nasal polyps (CRSwNP):

    CRSwNP criteria: Patient is ≥18 years of age AND has chronic rhinosinusitis with bilateral nasal polyps AND has inadequate response to intranasal corticosteroids (documented run-in) AND meets trial-aligned objective criteria (eg, total NPS ≥5 with ≥2 in each nostril or Meltzer score ≥2 bilaterally or endoscopic/CT evidence as specified);age ≥18; NPS ≥5 with ≥2 per nostril

    Omalizumab is an add-on maintenance treatment for CRSwNP based on POLYP 1 and POLYP 2 trials.

    Chronic Spontaneous Urticaria (CSU) — evidence-based use

    Covered when ALL of the following are met:

    CSU initial criteria: Diagnosis of chronic spontaneous/idiopathic urticaria with hives and/or angioedema for ≥6 weeks; and inadequate response to second-generation H1-antihistamines at standard dose with documented attempt at uptitration up to 4x if tolerated; and consideration of omalizumab 300 mg monthly per RCT evidence for up to 6 months;duration ≥6 weeks

    High-quality RCT evidence supports 300 mg/month for symptom and quality-of-life improvement for up to 6 months.

    Nasal Polyposis — trial-aligned coverage

    Covered when ALL of the following are met (trial-aligned criteria):

    NP initial criteria: Adult patient (≥18 years) with bilateral nasal polyps; and inadequate response to intranasal corticosteroid therapy with documented run-in on mometasone; and baseline total NPS ≥5 with NPS ≥2 in each nostril; and baseline weekly average nasal congestion score >1;NPS ≥5 and NCS >1

    POLYP 1 and POLYP 2 required these entry criteria and demonstrated significant improvements in NPS and nasal congestion when omalizumab was added to intranasal steroid therapy over 24 weeks.

    Pediatric Asthma (6 to <12 years) — selective coverage/consideration

    Considered when ALL of the following are met:

    Pediatric asthma criteria: Age 6 to <12 years with moderate-to-severe persistent allergic (IgE-mediated) asthma; and inadequate control despite medium- to high-dose inhaled corticosteroids with or without other controller medications; and positive perennial allergen sensitivity and serum IgE within pediatric dosing range used in trials; and clinician documents expected benefit and monitoring plan;age 6-<12 with prior controller therapy; IgE 30–1300 IU/mL

    Trials in this age group show exacerbation reduction but guideline and HTA recommendations vary; risk-benefit and cost-effectiveness considerations apply.

    Allergic Bronchopulmonary Aspergillosis (ABPA)

    Coverage for ABPA is investigational/conditional and may require case-by-case review based on available evidence:

    ABPA evidence summary: (1) Randomized evidence is limited (only one small terminated RCT identified) and recruitment challenges limit conclusions; (2) Systematic reviews and meta-analyses of case series report reductions in exacerbations, oral corticosteroid use, and improved FEV1 and asthma control after omalizumab; (3) Use may be considered when steroid-sparing is needed and alternative therapies are inadequate, with close monitoring and documentation and preferably within case review or trial context;limited RCT data

    Large prospective RCTs are lacking; meta-analysis (Jin et al) reported reduced exacerbations and OCS use but evidence quality is limited by observational designs.

    Evidence-based coverage considerations by indication

    Coverage considerations should reflect the evidence strength per indication:

    ABPA: Evidence includes one small terminated RCT and systematic reviews of case series suggesting benefit (reduced exacerbations, decreased OCS use, improved FEV1) but data are limited; consider coverage only in refractory disease after documented standard therapy trials and inability to taper steroids.
    Bullous pemphigoid: Systematic reviews and case series report high response rates (~87.5% overall; ~55% complete response) in refractory bullous pemphigoid but evidence is observational; consider for refractory disease after standard therapies have failed.
    Chronic autoimmune urticaria: Multiple case series and small trials show substantial efficacy in antihistamine-refractory CAU; guidelines/UpToDate support omalizumab for CU not controlled with H1 antihistamines in patients ≥12 years.
    Atopic dermatitis/eczema: Evidence is mixed (small RCTs and case series) and larger RCTs are needed; routine use is investigational pending robust trial results.
    Cutaneous/systemic mastocytosis: Case reports and small series indicate symptomatic improvement in some patients, but evidence is preliminary and may support use in selected refractory cases with specialist documentation and case review.

    Other Indications — evidence synopsis

    Evidence-based summary for off-label/other indications discussed in this section:

    Indications with some supportive evidence: Chronic autoimmune urticaria, cutaneous/systemic mastocytosis, chronic eosinophilic pneumonia (case report), food allergy (monotherapy or adjunct to OIT supported by systematic review/meta-analysis), aspirin-exacerbated respiratory disease desensitization adjunct, urticarial vasculitis, insulin allergy (select case reports), seasonal allergen-related asthma when allergic to seasonal triggers and severe; evidence ranges from randomized trials for some uses to case reports and series for others, and many uses remain investigational.

    Use as adjunct to allergen immunotherapy

    Background evidence indicates potential benefit in adjunctive settings

    Adjunct to immunotherapy evidence: Randomized trial (Kopp et al) showed omalizumab added to depigmented specific immunotherapy reduced seasonal symptom load versus SIT alone and improved asthma and quality-of-life measures; other reviews and case reports indicate omalizumab can reduce adverse reactions when used with allergen immunotherapy, but larger RCTs are needed.

    Urticarial vasculitis

    Case reports and small series for urticarial vasculitis

    Urticarial vasculitis reports: Multiple case reports (including reports of 300 mg every 4 weeks achieving remission) suggest omalizumab may be effective for refractory urticarial vasculitis, but randomized data are lacking and use remains investigational.

    IgE level and dosing range considerations

    Evidence and discussion regarding IgE level ranges and populations outside dosing tables

    IgE considerations: Trials and reports include patients with baseline IgE both within and above traditional dosing ranges. Some registry and observational data report clinical improvement with omalizumab when IgE >700 IU/mL, but evidence is limited and often observational; pediatric allowable IgE upper limit may extend to 1300 IU/mL for ages 6–11 per cited sources; payers may require justification when IgE is outside standard adult range.Adults: 30–700 IU/mL; Children 6–11: 30–1300 IU/mL

    Monitoring IgE during therapy is not medically necessary for dose determination.

    FeNO as predictor of omalizumab response

    Use of biomarkers to predict response

    FeNO-guided selection: Modeled analysis suggests using FeNO >19.5 ppb to select patients for a 12-week omalizumab trial reduces expected cost per responder versus empiric trial; prospective validation is needed before routine implementation.>19.5 ppb

    May inform payer biomarker requirements but needs validation.

    All indications for omalizumab (Xolair) that are not expressly listed in this policy are considered experimental and investigational. Examples called out in the policy include allergic bronchopulmonary aspergillosis (ABPA), allergic conditions without asthma, allergic rhinitis, atopic dermatitis/eczema, eosinophilic esophagitis, food allergy, urticarial vasculitis, cutaneous mastocytosis, and use as an adjunct to subcutaneous immunotherapy. Requests for these unlisted indications should be supported by high-quality evidence and may be reviewed on a case-by-case basis; absent adequate evidence, coverage is typically not provided.

    Omalizumab is not indicated for relief of acute bronchospasm or status asthmaticus. For the allergic asthma indication, dosing is determined by baseline total serum IgE and body weight; the FDA label specifies a baseline IgE entry range of 30–700 IU/mL (and a maximum body weight of 150 kg) for dose calculation. Re-testing of IgE during active therapy should not be used to alter dose because total serum IgE levels rise after administration of omalizumab.

    Use of omalizumab in children younger than 6 years is not supported by the evidence cited in this policy. Pediatric trial data in the 6 to <12 year age group show some reduction in exacerbations, but guideline and HTA assessments have raised concerns about modest efficacy versus safety and cost, and several bodies recommend limiting routine use to older pediatric or adolescent patients.

    When requested for indications that lack controlled trial evidence, such uses may be excluded from routine coverage. The policy cites limited or terminated randomized trials and predominance of case series for several indications (for example, ABPA in people with cystic fibrosis), and indicates that absence of high-quality RCT data is a rationale for treating such indications as investigational unless strong clinical justification is provided.

    For eosinophilic esophagitis (EoE), available randomized trial evidence did not demonstrate symptomatic or histologic benefit with omalizumab. A prospective, randomized, double‑blind, placebo‑controlled trial reported no reduction in EoE symptoms or esophageal tissue eosinophil counts compared with placebo, and therefore omalizumab is not supported for EoE based on current trial data.

    The available evidence for omalizumab in non‑atopic (non‑allergic) asthma is preliminary. Small mechanistic and early clinical studies suggest biological effects (for example, reduction in FcεRI expression) and possible clinical benefit, but data are insufficient to establish routine coverage for non‑atopic asthma. The document lists non‑allergic asthma among indications considered investigational until stronger RCT evidence is available.

    Key: NA — not approved and no data available for this age group. (This designation is used in the inhaled corticosteroid dosing table entries where certain pediatric dose categories are marked as NA because the product is not approved or data are lacking for that age group.)

    Re‑testing of total serum IgE during the course of omalizumab therapy is not considered medically necessary for dose determination because total serum IgE levels increase after administration and remain elevated for up to one year; the dose should be based on the pre‑treatment IgE measured before the start of therapy (with re‑testing only after interruptions of ≥1 year).

    Use of omalizumab for indications lacking FDA approval or compendial support may be denied or considered not medically necessary. The policy lists numerous off‑label indications as experimental/investigational and notes that requests for such uses should be supported by robust evidence; absent such support, coverage for non‑labeled indications is not routinely provided.

    For cystic fibrosis patients with allergic bronchopulmonary aspergillosis (ABPA), randomized trial evidence is insufficient. The Cochrane reviews identified only one small, prematurely terminated randomized trial (n≈14) with incomplete data and a higher rate of serious adverse events in the omalizumab arm; consequently, routine coverage for ABPA in CF is not supported without clear clinical justification and case review.

    Use of omalizumab for atopic dermatitis/eczema is not established. Although biologic approaches including anti‑IgE therapy have theoretical rationale and small studies exist, large randomized controlled trial evidence demonstrating consistent clinical benefit is lacking; therefore routine use for atopic dermatitis is generally considered not medically necessary outside of clinical trials or well‑documented refractory cases.

    The policy reiterates that omalizumab is not supported for eosinophilic esophagitis: a randomized, double‑blind, placebo‑controlled trial in adults showed no improvement in symptoms or tissue eosinophil counts with omalizumab versus placebo, so EoE is not an evidence‑based indication for routine coverage.

    Use of omalizumab in patients with baseline total serum IgE substantially above the labeled adult dosing range remains inadequately supported by high‑quality evidence. Registry and retrospective reports include patients with IgE >700 IU/mL and suggest possible benefit, but the data are observational and limited. The policy indicates that treatment in adults with IgE well above 700 IU/mL lacks robust RCT support and may require strong justification for coverage.

    Coding Guidance

    Other CPT codes related to CPBCPT
    95012Nitric oxide expired gas determination.
    31231Nasal endoscopy, diagnostic, unilateral or bilateral (separate procedure).
    31233Nasal/sinus endoscopy, diagnostic; with maxillary sinusoscopy (via inferior meatus or canine fossa puncture).
    31235With sphenoid sinusoscopy (via puncture of sphenoidal face or cannulation of ostium).
    70486CT, maxillofacial area; without contrast.
    70487CT, with contrast.
    70488CT without contrast followed by contrast (with further sections).
    95004-95079Allergy Testing series.
    96372Therapeutic injection; subcutaneous or intramuscular.
    96401-96549Chemotherapy administration.
    1–10 of 12
    1/2
    Covered HCPCS CodesHCPCSCovered
    J2357Injection, omalizumab, 5 mg.
    Other HCPCS codes related to CPBHCPCS
    J2182Injection, mepolizumab, 1 mg [not covered in combination with omalizumab].
    J2356Injection, tezepelumab-ekko, 1 mg.
    J2786Injection, reslizumab, 1 mg [not covered in combination with omalizumab].
    ICD-10 codes covered if selection criteria are metICD-10Covered
    J45.40-J45.52Moderate persistent and severe persistent asthma [uncontrolled asthma].
    L50.8Other urticaria [chronic spontaneous].
    D47.02Systemic mastocytosis.
    J32.0-J32.9Chronic sinusitis.
    J33.0-J33.9Nasal polyps.
    T45.1X5A-T45.1X5SAdverse effect of antineoplastic and immunosuppressive drugs [Immune checkpoint inhibitor-related toxicity].
    ICD-10 codes not covered / relatedICD-10Not Covered
    B44.81Allergic bronchopulmonary aspergillosis.
    D47.01Cutaneous mastocytosis.
    D89.40-D89.49Mast cell activation syndrome and related disorders.
    J30.1-J30.9Allergic rhinitis.
    J82Pulmonary eosinophilia, not elsewhere classified.
    K20.0Eosinophilic esophagitis.
    K52.81Eosinophilic gastritis or gastroenteritis.
    L12.0-L12.9Pemphigoid.
    L20.0-L20.89Atopic dermatitis.
    L27.2Dermatitis due to ingested food.
    1–10 of 21
    1/3
    Relevant ICD-10 CodesICD-10
    L95.8Other vasculitis limited to the skin [urticarial vasculitis]
    M30.1Polyarteritis with lung involvement [Churg-Strauss] [eosinophilic granulomatosis with polyangiitis]
    Q82.2Congenital cutaneous mastocytosis
    U07.1COVID-19
    Z11.52Encounter for screening for COVID-19
    Z51.89Encounter for other specified aftercare [need for desensitization to allergens]
    Z88.6Allergy status to analgesic agent status [inhibition of respiratory reaction during aspirin desensitization in individuals with aspirin exacerbated respiratory disease]
    Z91.010 - Z91.038Food and insect allergy status
    Z91.040Latex allergy status
    Z91.049, Z91.09Other allergy, other than to medicinal agents [atopy to perennial aeroallergen with positive skin test or in vitro reactivity]
    Baseline total serum IgE — asthma
    Baseline total serum IgE for asthma dosing>= 30 IU/mL (pre-treatment) — dose/frequency determined by baseline total serum IgE and body weight using prescribing‑information tables
    Role of IgE in dosingAsthma and CRSwNP dosing use baseline total serum IgE and patient weight to select mg and interval (see Full Prescribing Information)
    Repeat IgE testing during therapyTotal serum IgE rises during treatment and remains elevated; re‑testing during therapy is not useful for dose determination (interruptions ≥1 year require re‑testing)
    Total serum IgE — adult eligibility range
    FDA adult entry-rangeTotal serum IgE 30 to 700 IU/mL (adults) — eligibility per FDA asthma labeling
    Weight limit for asthma dosingPatient weight ≤150 kg considered in dosing calculations (adult asthma)
    RationaleDose and frequency are determined by serum IgE measured before treatment and body weight; elevated IgE during treatment precludes monitoring by repeat levels
    Nasal Polyp Score (NPS) — trial criteria
    NPS scoring methodEndoscopic NPS scored 0–4 per nostril (total 0–8)
    Trial entry threshold (POLYP trials)Total NPS ≥5 with NPS ≥2 in each nostril required for pivotal trials
    Additional trial requirementBaseline weekly average nasal congestion score >1 and run‑in on nasal mometasone documented
    Total serum IgE entry‑range (by age)
    Adult IgE entry-rangeAdults: 30 to 700 IU/mL (standard dosing range)
    Pediatric 6–11 yrs upper rangeChildren 6 to <12 years: baseline total serum IgE 30 to 1,300 IU/mL referenced in pediatric studies/expert statement
    ImplicationPediatric dosing tables differ; use age‑appropriate prescribing‑information tables for dose determination
    FeNO threshold used in modeled analysis
    FeNO selection threshold (modeled)>19.5 ppb — FeNO >19.5 ppb used in modeled analysis to select patients for an omalizumab trial
    Policy noteModeled strategy showed lower expected cost per responder versus empiric trial; prospective validation recommended
    Inhaled corticosteroid dosing categories — reference tables
    ICS dose mappings includedPolicy appendix lists multiple inhaled corticosteroid dose thresholds by product and formulation (e.g., fluticasone HFA 80 mcg/puff mappings and budesonide DPI puffs/dose conversions)
    PurposeUsed to define medium‑to‑high‑dose inhaled corticosteroid for step‑therapy and asthma control assessment
    MDI vs DPI reportingMDI dosages expressed as actuator dose; DPI doses expressed as amount in inhaler after actuation — use these conventions when assessing documented ICS regimens

    Provider Actions & Prior Authorization

    Prior Authorization

    Precertification required

    Precertification of omalizumab (Xolair) is required of all Aetna participating providers and members in applicable plan designs. For precertification call (866) 752-7021 or fax (888) 267-3277. Statement of Medical Necessity (SMN) precertification forms are available from the Specialty Pharmacy Precertification resources. Lack of precertification or failure to meet authorization requirements may result in denial of coverage. Continuation requests must meet all initial authorization criteria.

    • Precertification phone/fax: (866) 752-7021 / (888) 267-3277
    • SMN forms: Specialty Pharmacy Precertification
    Prior Authorization

    Prior authorization for indication verification

    Prior authorization should confirm that the requested use meets the FDA‑approved indication criteria (age limits, evidence of perennial aeroallergen sensitization for asthma, baseline total serum IgE and weight when dosing for asthma/CRSwNP). For non‑FDA or off‑label indications, prior authorization should include clinical rationale and supporting evidence.

    • Verify age and indication per FDA labeling
    • Document evidence of perennial aeroallergen sensitization when treating asthma
    • For off‑label uses, submit detailed clinical rationale and supporting literature
    Documentation Required

    Confirm diagnosis and prior therapy

    For chronic spontaneous urticaria (CSU), prior authorization must document that symptoms have persisted ≥6 weeks and that the member remained symptomatic despite treatment with second‑generation H1‑antihistamines, including attempted updosing (up to 4× licensed dose) when clinically appropriate. For chronic rhinosinusitis with nasal polyps (CRSwNP), document an inadequate response to daily intranasal corticosteroids and provide baseline nasal polyp score (NPS) and nasal congestion scores as available.

    • CSU: symptoms ≥6 weeks; inadequate response to 2nd‑generation H1 antihistamines including updosing up to 4×
    • CRSwNP: documentation of continued intranasal corticosteroid use during treatment (unless contraindicated)
    • Provide baseline NPS (total ≥5 with ≥2 per nostril) and baseline nasal congestion score (average >1) if available
    Step Therapy

    Prior therapy and documentation expectations

    For chronic urticaria, member must have had an inadequate response to maximized therapy with second‑generation H1‑antihistamines (including updosing up to 4×) prior to consideration of omalizumab. For other investigational or less established indications (e.g., bullous pemphigoid, mast cell disorders, ABPA, atopic dermatitis), conventional systemic therapies are expected first‑line and prior authorization should document prior therapies tried, severity, duration, objective measures (e.g., biopsy results for bullous pemphigoid), and refractory status.

    • CU: document failure of high‑dose (up to 4×) 2nd‑generation H1 antihistamines
    • BP: document number and type of prior therapies failed and refractory status
    • Other indications: document severity, duration, objective measures and rationale for omalizumab after standard therapy
    Documentation Required

    FeNO‑guided trial or documentation of response

    FeNO measurement may be used to identify likely responders to omalizumab in asthma. Some models use a threshold >19.5 ppb to select patients for an initial omalizumab trial; documentation of FeNO and/or clinical response to a trial of therapy may be requested during prior authorization.

    • Consider FeNO >19.5 ppb to identify likely responders
    • If a FeNO‑guided trial was used, include results and documentation of response to the trial
    Documentation Required

    Baseline IgE documentation and dosing notes

    Baseline total serum IgE measurement and body weight are required for dose determination in asthma and CRSwNP per the Xolair prescribing information. Note that total serum IgE increases while on therapy; re‑testing during treatment is not useful for dose adjustment. For interruptions ≥1 year, re‑test total serum IgE for dosing.

    • Obtain baseline total serum IgE prior to initiating therapy for asthma and CRSwNP
    • Record body weight used for dosing calculations
    • If treatment interrupted ≥1 year, re‑measure total serum IgE for dose determination
    Note

    Reference prescribing information for dosing/safety

    Refer to the Xolair (omalizumab) Prescribing Information (Genentech, revised March 2023) and EMA product information for authoritative dosing tables, administration guidance, and safety warnings (including black box warning for anaphylaxis). Prior authorization reviewers will reference the prescribing information for dose and safety validation.

    • Xolair Prescribing Information (FDA) – Genentech, revised March 2023
    • Xolair EMA Product Information
    Documentation Required

    Nasal polyposis enrollment criteria (trial‑based)

    Nasal polyposis enrollment criteria for the pivotal trials required inadequate response to nasal corticosteroids during a run‑in and evidence of bilateral polyps with NPS ≥5 (with ≥2 in each nostril) and average nasal congestion score >1. Prior authorization for CRSwNP should include documentation that mirrors trial enrollment (use of intranasal corticosteroid run‑in and baseline NPS/NCS when available).

    • Document use of intranasal corticosteroid (e.g., mometasone) during a run‑in period unless contraindicated
    • Provide endoscopic/CT/rhinoscopy evidence of bilateral polyps and NPS scoring if available
    • Provide baseline nasal congestion score (daily 0–3 scale)
    Step Therapy

    No additional step therapy requirements specified

    There are no additional step‑therapy requirements specified beyond the clinical criteria already described for each indication in these sections. Coverage determinations remain subject to plan benefits and the Clinical Policy Bulletin; the bulletin is not a contract and does not replace clinical judgment.

    • Initial and continuation criteria must be met for authorization
    • Policy does not add extra step therapy beyond indication‑specific requirements

    Background

    Background: Omalizumab (Xolair) is a humanized anti‑IgE monoclonal antibody approved by the U.S. Food and Drug Administration for allergic (IgE‑mediated) asthma in patients aged ≥6 years, for chronic spontaneous urticaria (CSU) in patients aged ≥12 years, and for add‑on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults ≥18 years. The agent is administered subcutaneously and dosing for asthma and CRSwNP is calculated from baseline total serum IgE and patient body weight, whereas CSU dosing is a fixed 150 mg or 300 mg subcutaneous dose every 4 weeks per clinical guidance and trials.

    Definitions

    CSU — Chronic spontaneous urticaria
    DefinitionChronic spontaneous urticaria (CSU): recurrent hives and/or angioedema persisting ≥6 weeks
    FDA indication ageOmalizumab indicated for CSU in patients ≥12 years who remain symptomatic despite H1 antihistamines
    Typical CSU dosingRCT evidence supports 300 mg by subcutaneous injection every 4 weeks for treatment‑refractory CSU
    CRSwNP — Chronic rhinosinusitis with nasal polyps
    DefinitionChronic rhinosinusitis with nasal polyps (CRSwNP): chronic sinonasal inflammation with bilateral nasal polyps
    FDA indication ageOmalizumab indicated as add‑on maintenance for CRSwNP in adults ≥18 years with inadequate response to nasal corticosteroids
    Trial basisApproval based on POLYP 1 and POLYP 2 Phase III trials demonstrating NPS and nasal congestion improvements
    IgE eligibility — FDA labeling for allergic asthma
    Label IgE requirementFDA prescribing information requires baseline total serum IgE between 30 and 700 IU/mL for allergic asthma dosing calculations
    Weight considerationDosing tables also incorporate body weight (kg) — weight affects dose selection and maximum single‑dose constraints
    Clinical noteTotal serum IgE rises after treatment due to complexes; baseline measurement is required prior to initiation
    CSU — indication and criteria
    CSU diagnostic durationCSU defined by recurrent hives/angioedema for >6 weeks
    Treatment positioningOmalizumab indicated for patients ≥12 years remaining symptomatic despite H1 antihistamines, including consideration of up‑dosing to 4× prior to escalation
    EvidenceMultiple RCTs support efficacy and safety of omalizumab (300 mg monthly) for CSU up to 6 months
    Chronic spontaneous (idiopathic) urticaria — definition
    Clinical definitionChronic spontaneous (idiopathic) urticaria: hives, angioedema, or both persisting ≥6 weeks
    AssessmentEvaluate for other causes and document inadequate response to antihistamines before omalizumab consideration
    Nasal Polyp Score (NPS) — scoring and trial thresholds
    Scoring systemEndoscopic NPS: 0–4 per nostril, total 0–8
    Trial enrollment requirementPOLYP trials required total NPS ≥5 with ≥2 in each nostril — used as coverage entry criterion for CRSwNP in policy
    Measurement methodNPS measured via nasal endoscopy; baseline nasal congestion score and run‑in on mometasone were also required in trials
    ABPA — evidence summary
    ABPA descriptionAllergic bronchopulmonary aspergillosis (ABPA): a hypersensitivity pulmonary disorder associated with Aspergillus species
    Evidence baseRandomized evidence is very limited (only 1 small terminated RCT in CF‑related ABPA); systematic reviews/meta‑analyses of case series report reductions in exacerbations and steroid use but are limited by study design
    Coverage stanceABPA considered investigational/conditional — may require case‑by‑case review with documentation of steroid‑sparing need
    Chronic autoimmune urticaria (CAU)
    CAU definitionChronic autoimmune urticaria (CAU): chronic urticaria with autoantibodies (≈45%) against high‑affinity IgE receptor or IgE
    Response evidenceOmalizumab has shown efficacy in refractory CAU in small studies and case series; may benefit patients not controlled with antihistamines
    Diagnostic noteDiagnosis may require in‑vivo and in‑vitro testing (e.g., autologous serum skin test, basophil histamine release) for confirmation
    Chronic Autoimmune Urticaria (CAU) — subset note
    Subset definitionCAU is a subset of chronic urticaria with detectable autoantibodies (often vs high‑affinity IgE receptor)
    Therapeutic implicationMay preferentially benefit from omalizumab when autoantibody‑mediated mechanisms are documented and antihistamines have failed
    Mast Cell Disorders — overview
    ScopeMast cell disorders: heterogeneous group including systemic mastocytosis characterized by mediator‑related symptoms (cutaneous, GI, anaphylaxis)
    Evidence and useCase series and cohort data suggest symptom improvement with omalizumab in selected refractory patients but high‑quality trials are limited
    EVALI — definition and counseling note
    DefinitionEVALI: e‑cigarette, or vaping, product use‑associated lung injury linked mainly to THC and/or vitamin E acetate in vaping products
    Clinical implicationProviders should counsel on vaping risks; policy references FDA/CDC guidance
    MDI vs DPI dose reporting
    MDI dose reportingMDI dosages are expressed as the actuator dose — the amount leaving the actuator and delivered to the patient
    DPI dose reportingDPI doses are expressed as the amount of drug in the inhaler following actuation
    Use in policyAppendix inhaled‑corticosteroid tables use these conventions when defining medium/high ICS doses for step‑therapy assessments
    Omalizumab (Xolair) — drug summary
    Drug classOmalizumab (Xolair): humanized anti‑IgE monoclonal antibody for IgE‑mediated conditions (allergic asthma, CSU, CRSwNP)
    FDA‑approved indications summaryApproved for allergic asthma (≥6 yrs), chronic spontaneous urticaria (≥12 yrs), and CRSwNP (≥18 yrs) as described in prescribing information
    Safety noteCarries a black‑box warning for risk of anaphylaxis; monitor per prescribing information

    Coding & Billing Summary

    Covered drug HCPCS and related codes
    Covered HCPCS codeJ2357 — Injection, omalizumab, 5 mg (covered if selection criteria met)
    Related CPT codesIncludes allergy testing (95004–95079), nasal endoscopy (31231, 31233, 31235), CT sinus codes (70486–70488) and injection administration (96372)
    Other biologics listedOther HCPCS referenced (J2182, J2356, J2786) — not to be used in combination with omalizumab

    Revision History